Navigation Links
A Human Brain Gene Could Hold Clues On The Evolution Of Brain Capacity

olecular biology to characterize the gene, identify the tissues in which it is active, and begin the search to understand its function.

HAR1 is part of two overlapping genes. One of those genes, called HAR1F, is active in special nerve cells, called Cajal-Retzius neurons, that appear early in embryonic development and play a critical role in the formation of the layered structure of the human cerebral cortex. Cajal-Retzius neurons release a protein called reelin that guides the growth of neurons and the formation of connections among them. HAR1F is active at the same time as the reelin gene.

"We don't know what it does, and we don't know if it interacts with reelin. But the evidence is very suggestive that this gene is important in the development of the cerebral cortex, and that's exciting because the human cortex is three times as large as it was in our predecessors," Haussler said. "Something caused our brains to evolve to be much larger and have more functions than the brains of other mammals."

Pollard, as a postdoctoral researcher at UCSC, was part of the international team that performed the initial analysis of the chimpanzee genome. She and Haussler then devised a computational strategy for using the chimp genome and comparative genomics to identify regions of the human genome that had evolved rapidly.

"When we developed this computational method, we weren't sure what we would find. It was very rewarding to find that this region that came out at the top of our list is potentially relevant to human evolution in an interesting way," Pollard said.

Pollard's analysis showed that HAR1 is essentially the same in all mammals except humans. There were only two differences between the chicken and chimp genomes in HAR1's sequence of 118 bases (bases are subunits of DNA, the As, Cs, Ts, and Gs that spell out the genetic code). This similarity means the DNA sequence remained unchanged over hundreds of millions o
'"/>




Page: 1 2 3 4

Related medicine news :

1. Human Genome Project Achieves Technological Triumph
2. First Vaccine Designed for Africa Cleared for Testing in Humans
3. Human gene number increases
4. Scientists found ancient Human Germ Killer
5. New standards for Human Research Safety
6. Human wasting disease linked to a gene
7. The Human Mad Cow Case
8. Human Growth Hormone Found To be Dangerous For Human Use
9. Human Antibody That Can Block SARS
10. Human immunity system can battle HIV.
11. Two New Human Papilloma virus (HPV) vaccines to prevent cervical cancer
Post Your Comments:
(Date:12/2/2008)...NGTON -- A new report from the Institute of Medici...ours and workloads to decrease the chances of fati...ning environment for these doctors in training. T...dents, work hours from the maximum average of 80 p...ate Medical Education (ACGME) in 2003, but rather ...
(Date:12/2/2008)... SAN DIEGO, Dec. 2 Stroller Stri...exercise program for new moms and their babies, ha...re for more than 40 years, has signed on as the co...ew partnership will strengthen the companies, shar.... , , "We are thrilled to have Pampers as o...
(Date:12/2/2008)... Comparator Study to Evaluate Efficacy of Commerci...WOODCLIFF LAKE, N.J., Dec. 2 Eisai... it plans to initiate the first clinical trial eva... injection) compared to Vidaza(R) (azacitidine) in...2 or high-risk myelodysplastic syndromes (MDS), a ...
(Date:12/2/2008)... Tenn., Dec. 2 Emdeon, a leading p...olutions for the healthcare industry,announced t...business,efficiency in healthcare. Emdeon unveile...ushealthcareindex.com ) to establish a national re... from a paper-based and phone-based,system to an ...
Breaking Medicine News(10 mins):Health News:Revised hours and workloads for medical residents needed to prevent 2Health News:Revised hours and workloads for medical residents needed to prevent 3Health News:Stroller Strides(R) Signs Pampers(R) as Premier Sponsor for 2009 2Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 2Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 3Health News:Emdeon Convenes Industry Forum to Monitor Business Efficiency in Healthcare 2Health News:Emdeon Convenes Industry Forum to Monitor Business Efficiency in Healthcare 3Health News:Emdeon Convenes Industry Forum to Monitor Business Efficiency in Healthcare 4
...pmental Biology, members of Dr. John Herr’s labora...eport the discovery// of a new protein within a sp...contraceptive drugs. “There’s considerable intere...es,” said Herr, who heads UVa’s Center for Researc...
...Medical Center have developed the first gene chip,...diagnosis of at// least five hereditary liver dise...causes of jaundice in children and adults, and pot...nt options. The Cincinnati Children's study resul...
...ad, medical science miracles will be a fact - tech...treatments will stand to// reshape the lives of pe...planning department at Eastern Virginia Medical Sc...sh Medical Journal based on these technologies. &...
...ck pain are effective, a new review of studies has...ological outcomes such as// depression and health-...’ experience of pain. “Because this analysis was...ative than previous reviews, we have the best evid...
Other Medicine News:Health News:Male Contraception: Discovery Stirring Interest Among Scientists, Drug Developers 2Health News:First Gene Chip Discovered by Cincinnati Researchers 2Health News:First Gene Chip Discovered by Cincinnati Researchers 3Health News:Medical Science Miracles – Coming Your Wa 2Health News:Psychological Treatments Improve Outcomes for Back Pain Sufferers 2Health News:Psychological Treatments Improve Outcomes for Back Pain Sufferers 3
(Date:11/25/2008)...ss Survival of Patients Receiving Litx versus Stan...ular Carcinoma , , BELLEVUE, Wash., Nov. 25...O) today announced the completion of enrollment in... Therapy(TM) (Litx(TM)) as a treatment for unresec...s hepatoma or primary liver cancer. , , The...
(Date:11/24/2008)...ewswire/ -- Takeda Pharmaceutical Company Limited ...earch & Development Center, Inc., U.S., announ... the U.S. Food and Drug Administration (FDA) recom...eatment of hyperuricemia in patients with gout. Th...ne panel member abstaining. The vote followed pres...
(Date:11/24/2008).../ -- Leaders of Schering-Plough Corporation (NYSE:... the company,s research pipeline, highlighting a r...entities in clinical trials or under regulatory re...search and development is adding strength and brea...mation," said Fred Hassan, chairman and CEO. "Our...
(Date:11/24/2008)... long-term commitment to hepatitis research , ...ll/ -- Schering-Plough Corporation (NYSE: SGP ) ...s lead investigational oral hepatitis C protease i...company believes boceprevir has the potential to b...bitor for treating chronic hepatitis C. The compa...
Breaking Medicine Technology:Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9Kidney cancer drug attacks a major type of acute myeloid leukemia 10430 1Kidney cancer drug attacks a major type of acute myeloid leukemia 10430 2Kidney cancer drug attacks a major type of acute myeloid leukemia 10430 3Using DNA scientists hunt for the roots of the modern potato 2050 1Using DNA scientists hunt for the roots of the modern potato 2050 2American Red Cross Launches 2008 National Public Service Advertising Campaign 10429 1American Red Cross Launches 2008 National Public Service Advertising Campaign 10429 2Flextronics Announces Third Quarter Results 10427 1Flextronics Announces Third Quarter Results 10427 2Flextronics Announces Third Quarter Results 10427 3Flextronics Announces Third Quarter Results 10427 4Flextronics Announces Third Quarter Results 10427 5Flextronics Announces Third Quarter Results 10427 6Flextronics Announces Third Quarter Results 10427 7Flextronics Announces Third Quarter Results 10427 8Flextronics Announces Third Quarter Results 10427 9Flextronics Announces Third Quarter Results 10427 10Flextronics Announces Third Quarter Results 10427 11Flextronics Announces Third Quarter Results 10427 12Flextronics Announces Third Quarter Results 10427 13Flextronics Announces Third Quarter Results 10427 14Flextronics Announces Third Quarter Results 10427 15Flextronics Announces Third Quarter Results 10427 16Flextronics Announces Third Quarter Results 10427 17Flextronics Announces Third Quarter Results 10427 18Flextronics Announces Third Quarter Results 10427 19
...Calif., June 05, 2007 /PRNewswire/ -- MAP,Pharmace... Phase 2,data from its MAP0004 migraine therapy cl...e Society Meeting at the Hyatt Regency,Chicago in ...was,accepted as a late-breaker, is entitled Rapid ...led Dihydroergotamine Mesylate,via a Novel Inhaler...
...une 05, 2007 /PRNewswire/ -- , Professor Home said...ppointing and,misleading in that they disregarded ...nt to patients and physicians. Most,significantly ...e,of any increase in cardiovascular death or death...T: Professor Philip Home, (44) 778-525-1736 , Ter...
Other Medicine Technology:MAP Pharmaceuticals to Present MAP0004 Phase 2 Clinical Data at the,American Headache Society Meeting 2
...e BP monitor is designed to automatically measure ...BP along with heart rate. It's a Blood Pressure mo...ergometer and pharmacological stress test environm...ronments., ,Tango excels where other BP monit...
BD Visiswab Cotton Swab
...l, Philips Zymed 1810 Series offers retrospective ... the operator the flexibility to adjust the algori...application beyond the basic 1810 and you have eve...matic style that best meets the challenges of each...
...s STG for PC captures, displays, replays and analy...be effective in evaluating heart illnesses, pneumo...ase.,It provides objective evidence as a complem...time-expanded waveform displays, Phonocardiogra...
Medicine Products: